Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Remon J, García-Campelo R, de Álava E, Vera R, Rodríguez-Peralto JL, Rodríguez-Lescure Á, Bellosillo B, Garrido P, Rojo F, Álvarez-Alegret R.

Clin Transl Oncol. 2019 Sep 26. doi: 10.1007/s12094-019-02211-x. [Epub ahead of print]

PMID:
31559582
2.

HER-family ligands promote acquired resistance to trastuzumab in gastric cancer.

Sampera A, Sánchez-Martín FJ, Arpí O, Visa L, Iglesias M, Menéndez S, Gaye É, Dalmases A, Clavé S, Gelabert-Baldrich M, Poulsen TT, Kragh M, Bellosillo B, Albanell J, Rovira A, Montagut C.

Mol Cancer Ther. 2019 Sep 4. pii: molcanther.0455.2019. doi: 10.1158/1535-7163.MCT-19-0455. [Epub ahead of print]

PMID:
31484705
3.

Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer.

Evrard SM, Clermont ET, Rouquette I, Murray S, Dintner S, Nam-Apostolopoulos YC, Bellosillo B, Rodriguez MV, Nadal E, Wiedorn KH, Melchior L, Andrew E, Jones M, Ridgway J, Frykman C, Lind L, Rot M, Kern I, Speel EJM, Roemen GMJM, Trincheri N, Freiberger SN, Rechsteiner M.

J Mol Diagn. 2019 Aug 22. pii: S1525-1578(19)30355-1. doi: 10.1016/j.jmoldx.2019.06.010. [Epub ahead of print]

4.

Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.

Berghoff AS, Bellosillo B, Caux C, de Langen A, Mazieres J, Normanno N, Preusser M, Provencio M, Rojo F, Wolf J, Zielinski CC.

ESMO Open. 2019 Jun 17;4(3):e000498. doi: 10.1136/esmoopen-2019-000498. eCollection 2019. Review.

5.

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma.

Chalela R, Bellosillo B, Curull V, Longarón R, Pascual-Guardia S, Badenes-Bonet D, Arriola E, Sánchez-Font A, Pijuan L, Gea J.

J Clin Med. 2019 Apr 17;8(4). pii: E529. doi: 10.3390/jcm8040529.

6.

Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.

Clavé S, Rodon N, Pijuan L, Díaz O, Lorenzo M, Rocha P, Taus Á, Blanco R, Bosch-Barrera J, Reguart N, de la Torre N, Oliveras G, Espinet B, Bellosillo B, Puig X, Arriola E, Salido M.

Clin Lung Cancer. 2019 Jul;20(4):e421-e429. doi: 10.1016/j.cllc.2019.02.008. Epub 2019 Feb 26.

PMID:
30898567
7.

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.

Vidal J, Bellosillo B, Santos Vivas C, García-Alfonso P, Carrato A, Cano MT, García-Carbonero R, Élez E, Losa F, Massutí B, Valladares-Ayerbes M, Viéitez JM, Manzano JL, Azuara D, Gallego J, Pairet S, Capellá G, Salazar R, Tabernero J, Aranda E, Montagut C.

Ann Oncol. 2019 Mar 1;30(3):439-446. doi: 10.1093/annonc/mdz005.

PMID:
30689692
8.

Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene that is epigenetically regulated.

Martínez-Calle N, Pascual M, Ordoñez R, Enériz ESJ, Kulis M, Miranda E, Guruceaga E, Segura V, Larráyoz MJ, Bellosillo B, Calasanz MJ, Besses C, Rifón J, Martín-Subero JI, Agirre X, Prosper F.

Haematologica. 2019 Aug;104(8):1572-1579. doi: 10.3324/haematol.2018.204917. Epub 2019 Jan 17.

9.

International external quality assurance of JAK2 V617F quantification.

Asp J, Skov V, Bellosillo B, Kristensen T, Lippert E, Dicker F, Schwarz J, Wojtaszewska M, Palmqvist L, Akiki S, Aggerholm A, Tolstrup Andersen M, Girodon F, Kjær L, Oppliger Leibundgut E, Pancrazzi A, Vorland M, Andrikovics H, Kralovics R, Cassinat B, Coucelo M, Eftimov A, Haslam K, Kusec R, Link-Lenczowska D, Lodé L, Matiakowska K, Naguib D, Navaglia F, Novotny GW, Percy MJ, Sudarikov A, Hermouet S, Pallisgaard N.

Ann Hematol. 2019 May;98(5):1111-1118. doi: 10.1007/s00277-018-3570-8. Epub 2018 Dec 8.

10.

Molecular analysis of peripheral lung adenocarcinoma in brush cytology obtained by EBUS plus fluoroscopy-guided bronchoscopy.

Sánchez-Font A, Chalela R, Martín-Ontiyuelo C, Albero-González R, Dalmases A, Longarón R, Alonso-Espinaco V, Curull V, Bellosillo B, Pijuan L.

Cancer Cytopathol. 2018 Oct;126(10):860-871. doi: 10.1002/cncy.22053. Epub 2018 Oct 6.

11.

Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer.

Prieto-Potin I, Montagut C, Bellosillo B, Evans M, Smith M, Melchior L, Reiltin W, Bennett M, Pennati V, Castiglione F, Bürrig KF, Cooper U, Dockhorn-Dworniczak B, Rossenbach C, Luna-Aguirre CM, Barrera-Saldaña HA, Machado JC, Costa JL, Yacobi R, Tabibian-Keissar H, Buglioni S, Ronchetti L, Douglas-Berger L, Dubbink HJ, Alorini M, Sabourin JC, Rojo F.

J Mol Diagn. 2018 Sep;20(5):664-676. doi: 10.1016/j.jmoldx.2018.05.008. Epub 2018 Jun 26.

PMID:
29959022
12.

Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma.

Taus Á, Camacho L, Rocha P, Hardy-Werbin M, Pijuan L, Piquer G, López E, Dalmases A, Longarón R, Clavé S, Salido M, Albanell J, Bellosillo B, Arriola E.

Clin Lung Cancer. 2018 Sep;19(5):387-394.e2. doi: 10.1016/j.cllc.2018.03.015. Epub 2018 Mar 23.

PMID:
29656868
13.

Utility of Human Papillomavirus Genotyping in the Management of Low-Grade Squamous Intraepithelial Lesions.

Solé-Sedeno JM, Mancebo G, Miralpeix E, Lloveras B, Bellosillo B, Alameda F, Carreras R.

J Low Genit Tract Dis. 2018 Jan;22(1):13-16. doi: 10.1097/LGT.0000000000000354.

PMID:
29271851
14.

Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.

Senín A, Fernández-Rodríguez C, Bellosillo B, Camacho L, Longarón R, Angona A, Besses C, Álvarez-Larrán A.

Ann Hematol. 2018 Mar;97(3):443-451. doi: 10.1007/s00277-017-3193-5. Epub 2017 Nov 27.

PMID:
29181548
15.

Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.

Chalela R, Curull V, Enríquez C, Pijuan L, Bellosillo B, Gea J.

J Thorac Dis. 2017 Jul;9(7):2142-2158. doi: 10.21037/jtd.2017.06.20. Review.

16.

Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.

Alvarez-Larrán A, Senín A, Fernández-Rodríguez C, Pereira A, Arellano-Rodrigo E, Gómez M, Ferrer-Marin F, Martínez-López J, Camacho L, Colomer D, Angona A, Navarro B, Cervantes F, Besses C, Bellosillo B, Hernández-Boluda JC.

Br J Haematol. 2017 Sep;178(5):764-771. doi: 10.1111/bjh.14762. Epub 2017 May 23.

PMID:
28542718
17.

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients.

Vidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, Orrillo M, Abalo A, Rodríguez C, Brozos E, Vidal Y, Candamio S, Vázquez F, Ruiz J, Guix M, Visa L, Sikri V, Albanell J, Bellosillo B, López R, Montagut C.

Ann Oncol. 2017 Jun 1;28(6):1325-1332. doi: 10.1093/annonc/mdx125.

18.

Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.

Brammeld JS, Petljak M, Martincorena I, Williams SP, Alonso LG, Dalmases A, Bellosillo B, Robles-Espinoza CD, Price S, Barthorpe S, Tarpey P, Alifrangis C, Bignell G, Vidal J, Young J, Stebbings L, Beal K, Stratton MR, Saez-Rodriguez J, Garnett M, Montagut C, Iorio F, McDermott U.

Genome Res. 2017 Apr;27(4):613-625. doi: 10.1101/gr.213546.116. Epub 2017 Feb 8.

19.

MicroRNAs 142-3p, miR-155 and miR-203 Are Deregulated in Gastric MALT Lymphomas Compared to Chronic Gastritis.

Fernández C, Bellosillo B, Ferraro M, Seoane A, Sánchez-González B, Pairet S, Pons A, Barranco L, Vela MC, Gimeno E, Colomo L, Besses C, Navarro A, Salar A.

Cancer Genomics Proteomics. 2017 Jan 2;14(1):75-82.

20.

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, Mussolin B, Baldi F, Buscarino M, Bartolini A, Valtorta E, Vidal J, Bellosillo B, Germano G, Pietrantonio F, Ponzetti A, Albanell J, Siena S, Sartore-Bianchi A, Di Nicolantonio F, Montagut C, Bardelli A.

Nat Commun. 2016 Dec 8;7:13665. doi: 10.1038/ncomms13665.

21.

Usefulness of p16INK4a staining for managing histological high-grade squamous intraepithelial cervical lesions.

Miralpeix E, Genovés J, Maria Solé-Sedeño J, Mancebo G, Lloveras B, Bellosillo B, Alameda F, Carreras R.

Mod Pathol. 2017 Feb;30(2):304-310. doi: 10.1038/modpathol.2016.168. Epub 2016 Oct 14.

22.

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer.

Solassol J, Vendrell J, Märkl B, Haas C, Bellosillo B, Montagut C, Smith M, O'Sullivan B, D'Haene N, Le Mercier M, Grauslund M, Melchior LC, Burt E, Cotter F, Stieber D, Schmitt FL, Motta V, Lauricella C, Colling R, Soilleux E, Fassan M, Mescoli C, Collin C, Pagès JC, Sillekens P.

PLoS One. 2016 Sep 29;11(9):e0163444. doi: 10.1371/journal.pone.0163444. eCollection 2016.

23.

Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing.

Angona A, Fernández-Rodríguez C, Alvarez-Larrán A, Camacho L, Longarón R, Torres E, Pairet S, Besses C, Bellosillo B.

Blood Cancer J. 2016 Aug 26;6(8):e463. doi: 10.1038/bcj.2016.75. No abstract available.

24.

Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.

Angona A, Alvarez-Larrán A, Bellosillo B, Longarón R, Camacho L, Fernández-Rodríguez MC, Pairet S, Besses C.

Leuk Res. 2016 Sep;48:11-5. doi: 10.1016/j.leukres.2016.06.009. Epub 2016 Jun 29.

PMID:
27427771
25.

Value of p16(INK4a) and Ki-67 Immunohistochemical Staining in Cervical Intraepithelial Neoplasia Grade 2 Biopsies as Biomarkers for Cervical Intraepithelial Neoplasia Grade 3 in Cone Results.

Miralpeix E, Solé-Sedeño JM, Mancebo G, Lloveras B, Bellosillo B, Carreras R, Alameda F.

Anal Quant Cytopathol Histpathol. 2016 Feb;38(1):1-8.

PMID:
27363060
26.

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.

Robles EF, Mena-Varas M, Barrio L, Merino-Cortes SV, Balogh P, Du MQ, Akasaka T, Parker A, Roa S, Panizo C, Martin-Guerrero I, Siebert R, Segura V, Agirre X, Macri-Pellizeri L, Aldaz B, Vilas-Zornoza A, Zhang S, Moody S, Calasanz MJ, Tousseyn T, Broccardo C, Brousset P, Campos-Sanchez E, Cobaleda C, Sanchez-Garcia I, Fernandez-Luna JL, Garcia-Muñoz R, Pena E, Bellosillo B, Salar A, Baptista MJ, Hernandez-Rivas JM, Gonzalez M, Terol MJ, Climent J, Ferrandez A, Sagaert X, Melnick AM, Prosper F, Oscier DG, Carrasco YR, Dyer MJ, Martinez-Climent JA.

Nat Commun. 2016 Jun 14;7:11889. doi: 10.1038/ncomms11889.

27.

Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.

Casadevall D, Vidal J, Gallardo F, Zuccarino F, Arumí-Uría M, Dalmases A, Bellosillo B, Montagut C.

J Med Case Rep. 2016 Jun 2;10(1):158. doi: 10.1186/s13256-016-0953-0.

28.

Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.

Azuara D, Santos C, Lopez-Doriga A, Grasselli J, Nadal M, Sanjuan X, Marin F, Vidal J, Montal R, Moreno V, Bellosillo B, Argiles G, Elez E, Dienstmann R, Montagut C, Tabernero J, Capellá G, Salazar R.

Mol Cancer Ther. 2016 May;15(5):1106-12. doi: 10.1158/1535-7163.MCT-15-0820. Epub 2016 Apr 1.

29.

miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia.

Navarro A, Pairet S, Álvarez-Larrán A, Pons A, Ferrer G, Longarón R, Fernández-Rodríguez C, Camacho L, Monzó M, Besses C, Bellosillo B.

Blood Cancer J. 2016 Mar 18;6:e406. doi: 10.1038/bcj.2016.10.

30.

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.

Sánchez-Martín FJ, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Cañadas I, Vidal J, Martinez A, Argilés G, Siravegna G, Arena S, Koefoed K, Visa L, Arpí O, Horak ID, Iglesias M, Stroh C, Kragh M, Rovira A, Albanell J, Tabernero J, Bardelli A, Montagut C.

Clin Cancer Res. 2016 Jul 1;22(13):3260-7. doi: 10.1158/1078-0432.CCR-15-2400. Epub 2016 Feb 17.

31.

STAT1 activation in association with JAK2 exon 12 mutations.

Godfrey AL, Chen E, Massie CE, Silber Y, Pagano F, Bellosillo B, Guglielmelli P, Harrison CN, Reilly JT, Stegelmann F, Bijou F, Lippert E, Boiron JM, Döhner K, Vannucchi AM, Besses C, Green AR.

Haematologica. 2016 Jan;101(1):e15-9. doi: 10.3324/haematol.2015.128546. Epub 2015 Dec 3. No abstract available.

32.

Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma.

Melchior L, Grauslund M, Bellosillo B, Montagut C, Torres E, Moragón E, Micalessi I, Frans J, Noten V, Bourgain C, Vriesema R, van der Geize R, Cokelaere K, Vercooren N, Crul K, Rüdiger T, Buchmüller D, Reijans M, Jans C.

Exp Mol Pathol. 2015 Dec;99(3):485-91. doi: 10.1016/j.yexmp.2015.09.004. Epub 2015 Sep 25.

PMID:
26407762
33.

Notch1 Pathway Activation Results from the Epigenetic Abrogation of Notch-Related MicroRNAs in Mycosis Fungoides.

Gallardo F, Sandoval J, Díaz-Lagares A, Garcia R, D'Altri T, González J, Alegre V, Servitje O, Crujeiras AB, Stefánsson ÓA, Espinet B, Hernández MI, Bellosillo B, Esteller M, Pujol RM, Bigas A, Espinosa L.

J Invest Dermatol. 2015 Dec;135(12):3144-3152. doi: 10.1038/jid.2015.328. Epub 2015 Aug 24.

34.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A.

Nat Med. 2015 Jul;21(7):827. doi: 10.1038/nm0715-827b. No abstract available.

PMID:
26151329
35.

Dynamics of JAK2 V617F allele burden of CD34+ haematopoietic progenitor cells in patients treated with ruxolitinib.

Angona A, Alvarez-Larrán A, Bellosillo B, Longarón R, Fernández-Rodríguez C, Besses C.

Br J Haematol. 2016 Feb;172(4):639-42. doi: 10.1111/bjh.13535. Epub 2015 Jun 26. No abstract available.

PMID:
26115187
36.

Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.

Fernández-Rodríguez C, Salar A, Navarro A, Gimeno E, Pairet S, Camacho L, Ferraro M, Serrano S, Besses C, Bellosillo B, Sanchez-Gonzalez B.

Leuk Lymphoma. 2016;57(3):692-9. doi: 10.3109/10428194.2015.1063143.

37.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A.

Nat Med. 2015 Jul;21(7):795-801. doi: 10.1038/nm.3870. Epub 2015 Jun 1. Erratum in: Nat Med. 2015 Jul;21(7):doi:10.1038/nm0715-827b. Erratum in: Nat Med. 2015 Jul;21(7):827.

38.

Molecular diagnostics of myeloproliferative neoplasms.

Langabeer SE, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K, Kjaer L, Lippert E, Mansier O, Oppliger Leibundgut E, Percy MJ, Porret N, Palmqvist L, Schwarz J, McMullin MF, Schnittger S, Pallisgaard N, Hermouet S; MPN&MPNr-EuroNet.

Eur J Haematol. 2015 Oct;95(4):270-9. doi: 10.1111/ejh.12578. Epub 2015 May 18. Review.

PMID:
25951317
39.

BRAF-induced tumorigenesis is IKKα-dependent but NF-κB-independent.

Margalef P, Colomer C, Villanueva A, Montagut C, Iglesias M, Bellosillo B, Salazar R, Martínez-Iniesta M, Bigas A, Espinosa L.

Sci Signal. 2015 Apr 21;8(373):ra38. doi: 10.1126/scisignal.2005886.

PMID:
25900832
40.

Cytoplasmic accumulation of NCoR in malignant melanoma: consequences of altered gene repression and prognostic significance.

Gallardo F, Padrón A, Garcia-Carbonell R, Rius C, González-Perez A, Arumí-Uria M, Iglesias M, Nonell L, Bellosillo B, Segura S, Pujol RM, Lopez-Bigas N, Bertran J, Bigas A, Espinosa L.

Oncotarget. 2015 Apr 20;6(11):9284-94.

41.

Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes.

Alvarez-Larrán A, Angona A, Ancochea A, García-Pallarols F, Fernández C, Longarón R, Bellosillo B, Besses C.

Eur J Haematol. 2016 Jan;96(1):83-9. doi: 10.1111/ejh.12552. Epub 2015 Apr 17.

PMID:
25810304
42.

Reproducibility of the cobas 4800 HPV test in the "grey zone".

Gomez S, Bellosillo B, Muset M, Lloveras B, Pijuan L, Gimeno J, Serrano S, Alameda F.

Anal Quant Cytopathol Histpathol. 2014 Oct;36(5):303-4. No abstract available.

PMID:
25804005
43.

Effect of mutation order on myeloproliferative neoplasms.

Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, Baxter EJ, Massie CE, Papaemmanuil E, Menon S, Godfrey AL, Dimitropoulou D, Guglielmelli P, Bellosillo B, Besses C, Döhner K, Harrison CN, Vassiliou GS, Vannucchi A, Campbell PJ, Green AR.

N Engl J Med. 2015 Feb 12;372(7):601-612. doi: 10.1056/NEJMoa1412098.

44.

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

Arena S, Bellosillo B, Siravegna G, Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S, González I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sánchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A, Montagut C.

Clin Cancer Res. 2015 May 1;21(9):2157-66. doi: 10.1158/1078-0432.CCR-14-2821. Epub 2015 Jan 26.

45.

Cervista HPV HR test for cervical cancer screening: a comparative study in the Catalonian population.

Alameda F, Garrote L, Mojal S, Sousa C, Muset M, LLoveras B, Bellosillo B, Saldanha C, Carreras R, Serrano S.

Arch Pathol Lab Med. 2015 Feb;139(2):241-4. doi: 10.5858/arpa.2014-0012-OA.

PMID:
25611107
46.

Urine human papillomavirus prevalence in women with high-grade cervical lesions.

Nicolau P, Mancebo G, Agramunt S, Solé-Sedeño JM, Bellosillo B, Muset MM, Lloveras B, Alameda F, Carreras R.

Eur J Obstet Gynecol Reprod Biol. 2014 Dec;183:12-5. doi: 10.1016/j.ejogrb.2014.10.005. Epub 2014 Oct 18.

PMID:
25461344
47.

[Essential thrombocythemia: baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients].

Angona A, Alvarez-Larrán A, Bellosillo B, Martínez-Avilés L, Garcia-Pallarols F, Longarón R, Ancochea À, Besses C.

Med Clin (Barc). 2015 Mar 15;144(6):247-53. doi: 10.1016/j.medcli.2014.04.029. Epub 2014 Sep 3. Spanish.

PMID:
25192581
48.

Identification of ALK gene alterations in urothelial carcinoma.

Bellmunt J, Selvarajah S, Rodig S, Salido M, de Muga S, Costa I, Bellosillo B, Werner L, Mullane S, Fay AP, O'Brien R, Barretina J, Minoche AE, Signoretti S, Montagut C, Himmelbauer H, Berman DM, Kantoff P, Choueiri TK, Rosenberg JE.

PLoS One. 2014 Aug 1;9(8):e103325. doi: 10.1371/journal.pone.0103325. eCollection 2014.

49.

Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.

Angona A, Alvarez-Larrán A, Bellosillo B, Martínez-Avilés L, Camacho L, Fernández-Rodríguez C, Pairet S, Longarón R, Ancochea Á, Senín A, Florensa L, Besses C.

Eur J Haematol. 2015 Mar;94(3):251-7. doi: 10.1111/ejh.12425. Epub 2014 Sep 13.

PMID:
25082530
50.

Paraffin treasures: do they last forever?

Ademà V, Torres E, Solé F, Serrano S, Bellosillo B.

Biopreserv Biobank. 2014 Aug;12(4):281-3. doi: 10.1089/bio.2014.0010. Epub 2014 Jul 30.

PMID:
25075953

Supplemental Content

Loading ...
Support Center